Also known as: Takeda Pharmaceutical
Takeda shares came under valuation scrutiny after recent gains and mixed pipeline news, including a DNL593 collaboration exit and positive Phase 3 data for zasocitinib. The analyses said the stock was trading close to or above widely followed fair value estimates, while DCF assumptions pointed to much higher implied value.
Pharmaceutical companies are increasingly partnering with biotechs developing RNA-targeting small molecules, driven by advances in RNA structural biology and the success of drugs like Roche's Evrysdi. The approach aims to address "undruggable" targets while offering oral availability advantages.
The global antibodies market is projected to reach $667.8 billion by 2032 with a 12.9% CAGR, while high throughput antibody production services are expected to grow at 11.2% CAGR through 2033, driven by biopharmaceutical development and monoclonal antibody therapeutics demand.
